Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Change in Accured Expenses (2019 - 2023)

Alx Oncology Holdings' Change in Accured Expenses history spans 5 years, with the latest figure at $4.7 million for Q4 2023.

  • For Q4 2023, Change in Accured Expenses rose 669.59% year-over-year to $4.7 million; the TTM value through Dec 2023 reached $11.2 million, up 59.73%, while the annual FY2025 figure was $2.0 million, 115.86% up from the prior year.
  • Change in Accured Expenses for Q4 2023 was $4.7 million at Alx Oncology Holdings, down from $8.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.3 million in Q3 2023 and bottomed at -$5.6 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $934000.0 (2020), against an average of $1.5 million.
  • The largest YoY upside for Change in Accured Expenses was 669.59% in 2023 against a maximum downside of 325.69% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $425000.0 in 2019, then skyrocketed by 603.06% to $3.0 million in 2020, then plummeted by 67.44% to $973000.0 in 2021, then crashed by 36.79% to $615000.0 in 2022, then soared by 669.59% to $4.7 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Change in Accured Expenses are $4.7 million (Q4 2023), $8.3 million (Q3 2023), and $3.7 million (Q2 2023).